Acusphere reports results from Imagify phase III trials

AuntMinnie.com staff writers
May 3, 2007

Ultrasound contrast developer Acusphere said that its Imagify (perflubutane polymer microspheres) contrast agent exceeded the criteria in accuracy and sensitivity in its second phase III clinical trial of the product.

The Watertown, MA-based company will use the results to support a new drug application (NDA) submission for Imagify in the fourth quarter of this year. The agent is designed to assess perfusion.

By AuntMinnie.com staff writers
May 4, 2007

Related Reading

Acusphere taps Bucceri for regulatory post, February 5, 2007

Acusphere to raise $23 million, December 7, 2006

Acusphere names Jaffe as VP, September 21, 2006

Acusphere licenses US contrast technology rights from GE, June 6, 2006

Acusphere to raise $38 million, April 7, 2006

Copyright © 2007 AuntMinnie.com

Latest in Ultrasound
Ultrasound Scanner Ultraviolet 400
Deep-learning algorithm improves liver fibrosis diagnosis
April 23, 2024
Screenshot (1142)
POCUS used widely in lung ultrasound applications
April 17, 2024
Img 2490
UltraCon: Expert talks ultrasound's role in imaging dense breasts
April 12, 2024
Andreas Giannakou, MD, from Brigham & Women’s Hospital and Harvard Medical School presents research highlighting how many women with early-stage HR+HER2- breast cancer and a negative presurgical axillary ultrasound can skip sentinel lymph node biopsy.
Negative axillary ultrasound can lead to breast biopsy omission
April 12, 2024
Related Stories
2007 04 03 14 27 03 706
Ultrasound
US is best bet in male breast, but only if imaging is absolutely necessary
2007 02 05 15 40 53 706
Ultrasound
Ultrasound continues to make inroads in breast imaging
2006 12 20 15 29 47 706
Ultrasound
Microflow imaging may boost prostate biopsy yield
2006 10 25 16 17 14 706
Ultrasound
U-Systems
More in Ultrasound
Deep-learning algorithm improves liver fibrosis diagnosis
By Amerigo Allegretto
An algorithm combining the Fibrosis-4 Index and an ultrasound deep-learning model could improve diagnostic accuracy for advanced liver fibrosis.
April 23, 2024
Ultrasound Scanner Ultraviolet 400
POCUS used widely in lung ultrasound applications
By Amerigo Allegretto
Some of the top domains for users of point-of-care ultrasound (POCUS) incorporate the technology for lung ultrasound applications.
April 17, 2024
Screenshot (1142)
UltraCon: Expert talks ultrasound's role in imaging dense breasts
By Amerigo Allegretto
Kibo Nam, PhD, from Thomas Jefferson University spoke with AuntMinnie.com about the current state of ultrasound in imaging dense breasts.
April 12, 2024
Img 2490
Negative axillary ultrasound can lead to breast biopsy omission
By Amerigo Allegretto
Many women with early-stage HR+HER2- breast cancer and a negative presurgical axillary ultrasound can skip sentinel lymph node biopsy.
April 12, 2024
Andreas Giannakou, MD, from Brigham & Women’s Hospital and Harvard Medical School presents research highlighting how many women with early-stage HR+HER2- breast cancer and a negative presurgical axillary ultrasound can skip sentinel lymph node biopsy.
UltraCon: Work-related MSK disorders tied to sonographer burnout
By Amerigo Allegretto
Work-related musculoskeletal (MSK) disorders are tied to work-related burnout among sonographers, according to research highlighted April 10 at UltraCon.
April 11, 2024
Jennifer Bagley from the University of Oklahoma Health Sciences Center presents results at UltraCon suggesting that work-related musculoskeletal disorders are tied to burnout among sonographers.
CEUS adds to locoregional therapy for liver disease
By Amerigo Allegretto
Contrast-enhanced ultrasound (CEUS) can improve locoregional therapy for treating metastatic disease of the liver.
April 11, 2024
Corinne Wessner from Thomas Jefferson University discusses early study results at UltraCon showing the potential of ultrasound-triggered microbubble destruction in treating liver disease.
UltraCon: Harmonic motion imaging tracks breast tumor response to chemo
By Amerigo Allegretto
Harmonic motion imaging can track mechanical property changes of breast tumors in response to neoadjuvant chemotherapy.
April 10, 2024
Yangpei Liu from Columbia University in Ney York City discussed findings at UltraCon suggesting that harmonic motion imaging could be a viable predictor of early treatment response.
UltraCon: Former Medtronic CEO talks ultrasound's future with AuntMinnie.com
By Amerigo Allegretto
Former Medtronic Chairman and CEO Omar Ishrak, PhD, spoke with AuntMinnie.com at UltraCon on the future of ultrasound and market creation.
April 10, 2024
Img 2502
UltraCon: Machine learning predicts sonographer burnout
By Amerigo Allegretto
Machine-learning approaches can predict burnout among sonographers, though established burnout indices may be enough, according to research presented April 9 at UltraCon.
April 9, 2024
Jennifer Bagley from the University of Oklahoma presents findings at UltraCon on the performance of two machine learning approaches in predicting burnout among sonographers.
UltraCon: Ultrasound empowers patients with prosthetic limbs
By Amerigo Allegretto
Gil Weinberg, PhD, a founding director of Georgia Tech's Center for Music Technology, spoke with AuntMinnie.com on ultrasound's use in prosthetics.
April 9, 2024
Img 2547
SRU releases consensus statement on endometriosis detection
By Amerigo Allegretto
The Society of Radiologists in Ultrasound (SRU) has issued a new expert consensus statement that aims to improve endometriosis evaluation.
April 9, 2024
Screenshot (1140)
UltraCon: Microflow imaging on par with CEUS for guiding tumor ablation
By Amerigo Allegretto
Microflow imaging performs just as well as contrast-enhanced ultrasound (CEUS) for guiding tumor ablation and may be an economic alternative.
April 9, 2024
Ziyue Hu, MD, from Sichuan Cancer Hospital in China highlighted findings at UltraCon, showing that along with comparable performance in treating thyroid nodules, microflow imaging is a less costly and invasive approach to tumor ablation than CEUS.
Page 1 of 509
Next Page